Weight Loss :: Sanofi’s Acomplia reimbursable in France for obese and type 2 diabetic patients
Sanofi-aventis announced that Acomplia? 20mg (rimonabant), the first drug in a new therapeutic class, the selective cannabinoid-1 receptor antagonists, has now been included in the list of pharmaceutical products reimbursable by the Social Security, by virtue of a decree dated March 22, 2007, published in the Official Journal of the French Republic.